Search Results - andrew+ewald

3 Results

Sort By:

Monoclonal Antibody for Cancer Metastasis

Unmet Need· It is projected that there will be about 1.9 million cancer cases, and 6 thousand cancer deaths within the US in the year 2023 (Siegel, 2021). mAb immunotherapy has been found to be less damaging and less invasive to rapidly dividing normal tissues when compared to current tumor therapy treatments such as surgery, radiation, and chemotherapy....

Published: 1/22/2026 | Inventor(s): Andrew Ewald, Matthew Dunworth, Shannon Radomski, Livia Casciola-Rosen, Antony Rosen

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > Biomarkers, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Autoantibodies as Anti-cancer Therapeutic Agents

TITLE: Autoantibodies as Anti-cancer Therapeutic AgentsCASE NUMBER: C13604UNMET NEED It has been speculated that autoimmunity and cancer were linked but the missing step was how to turn that concept into a robust method for identifying which specific auto antibodies would be generally effective. This problem was especially acute due...

Published: 1/22/2026 | Inventor(s): Andrew Ewald, Veena Padmanaban, Antony Rosen, Livia Casciola-Rosen

Keywords(s): Antibodies, Biologics, Breast Cancer, Cancers, Disease Indication, Immunotherapy, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology > Breast Cancer, Clinical and Disease Specializations > Women's Health, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Clinical and Disease Specializations > Oncology

Molecular Signatures of Invasive Cancer Subpopulations

C11851: Assay and molecular signature to identify invasive cancer cell population in tumorsNovelty: This invention is an assay for evaluating the metastatic potential of epithelial cancers, and a molecular signature linked to aggressive and invasive cancer subpopulations.Value Proposition: Inventors have developed an assay to enable stratification of...

Published: 1/22/2026 | Inventor(s): Kevin Cheung, Andrew Ewald

Keywords(s): Assay, Basic Research Biomarker, Biomarker, Cancer Cells, Cancers, Cell Model, Clinical Diagnostics, Diagnostic Biomarker, Discovery/Research Tools, Disease Indication, In Vitro Diagnostics, In Vitro Research Tool, Mechanism-of-action Biomarker, Prognostic Biomarker, Risk Stratification, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Epithelial Cancer